UnknownNot Applicable

Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients

Egypt100 participantsStarted 2020-10-15

Plain-language summary

Genetic polymorphisms of metabolic enzymes may influence the metabolism of Doxorubicin-Cyclophosphamide regimen in breast cancer patients. the investigators want to 1. evaluate the frequency or incidence of the genetic polymorphisms of CYP2C19 and ALDH3A1 in breast cancer patients, and 2. analyze the association between the genetic polymorphisms of CYP2C19 and ALDH3A1 and toxicities in breast cancer patients treated by Doxorubicin-Cyclophosphamide regimen therapy.

Who can participate

Age range18 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Confirmed diagnosis of breast cancer.
✓. Age ranging from 18 to 75 years old female.
✓. Patients will take Doxorubicin-Cyclophosphamide regimen as chemotherapy treatment.

Exclusion criteria

✕. Any other malignancy.
✕. Previous treatment for metastatic disease.
✕. Pregnancy or breastfeeding female.
✕. Inadequate bone marrow and cardiac function.
✕. Serious or uncontrolled medical conditions.

What they're measuring

The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients

Timeframe: Up to 24 weeks

The frequency of the genetic polymorphisms of ALDH3A1 in breast cancer patients

Timeframe: Up to 24 weeks

Trial details

NCT IDNCT04581967

SponsorDamanhour University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12-15

Contact for this trial

Hoda Salem, Ass. Prof

00201000007613 hsalem@ut.edu.sa

View on ClinicalTrials.gov More Breast Cancer Patients trials